Tango Therapeutics Pipeline
| Drug | Indication | Phase |
|---|
| TNG908 | MTAP-deleted solid tumors | Phase 1/2 |
| TNG462 | MTAP-deleted solid tumors | Phase 1/2 |
| TNG260 | STK11-mutant cancers (with anti-PD1) | Phase 1 |
| TNG348 | BRCA1/2-mutant cancers | Phase 1 |
| TNG712 | Undisclosed | Preclinical |